CN107405382A - 用于改善认知的方法和组合物 - Google Patents

用于改善认知的方法和组合物 Download PDF

Info

Publication number
CN107405382A
CN107405382A CN201680019604.8A CN201680019604A CN107405382A CN 107405382 A CN107405382 A CN 107405382A CN 201680019604 A CN201680019604 A CN 201680019604A CN 107405382 A CN107405382 A CN 107405382A
Authority
CN
China
Prior art keywords
klotho
method described
individual
cognitive
foregoing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680019604.8A
Other languages
English (en)
Chinese (zh)
Inventor
德娜·杜波
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Priority to CN202511208412.9A priority Critical patent/CN121102455A/zh
Publication of CN107405382A publication Critical patent/CN107405382A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201680019604.8A 2015-02-06 2016-02-05 用于改善认知的方法和组合物 Pending CN107405382A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202511208412.9A CN121102455A (zh) 2015-02-06 2016-02-05 用于改善认知的方法和组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562113300P 2015-02-06 2015-02-06
US62/113,300 2015-02-06
PCT/US2016/016842 WO2016127097A1 (en) 2015-02-06 2016-02-05 Methods and compositions for improved cognition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202511208412.9A Division CN121102455A (zh) 2015-02-06 2016-02-05 用于改善认知的方法和组合物

Publications (1)

Publication Number Publication Date
CN107405382A true CN107405382A (zh) 2017-11-28

Family

ID=56564770

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680019604.8A Pending CN107405382A (zh) 2015-02-06 2016-02-05 用于改善认知的方法和组合物
CN202511208412.9A Pending CN121102455A (zh) 2015-02-06 2016-02-05 用于改善认知的方法和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202511208412.9A Pending CN121102455A (zh) 2015-02-06 2016-02-05 用于改善认知的方法和组合物

Country Status (8)

Country Link
US (6) US10632180B2 (https=)
EP (2) EP3957317A1 (https=)
JP (1) JP6794363B2 (https=)
CN (2) CN107405382A (https=)
AU (2) AU2016215080B2 (https=)
CA (1) CA2974988A1 (https=)
HK (1) HK1246193A1 (https=)
WO (1) WO2016127097A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117797249A (zh) * 2023-11-14 2024-04-02 苏州祥沁医疗科技有限公司 基于mRNA的抗衰老抗老年痴呆预防及治疗疫苗
US12239694B2 (en) 2015-02-06 2025-03-04 The Regents Of The University Of California Methods and compositions for improved cognition

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017085317A1 (en) * 2015-11-19 2017-05-26 Universitat Autonoma De Barcelona Secreted splicing variant of mammal klotho as a medicament for cognition and behaviour impairments
JP2018184369A (ja) * 2017-04-26 2018-11-22 株式会社明治 知的作業能力向上用組成物および認知能力向上用組成物
WO2019140250A1 (en) * 2018-01-12 2019-07-18 New York University SOLUBLE α-KLOTH PROTEINS, PROTEIN FRAGMENTS, AND USES THEREOF
US20210106579A1 (en) * 2018-05-17 2021-04-15 Neuralstem, Inc. Amelioration of cognitive and motor deficits associated with alzheimer's
WO2020106997A1 (en) * 2018-11-21 2020-05-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods and materials for reducing age-related striated muscle and cognitive decline
EP4103223A4 (en) 2020-02-12 2024-05-29 The Regents of the University of California PLATELET FACTORS AND COGNITIVE IMPROVEMENT
US20230123357A1 (en) * 2020-03-04 2023-04-20 The Regents Of The University Of California Use of downstream factors in the klotho pathway to assess klotho activity
WO2024084400A2 (en) * 2022-10-17 2024-04-25 Bio Immunitas Ltd. Alpha 2 macroglobulin, soluble klotho and methods of use thereof
WO2024092238A1 (en) * 2022-10-28 2024-05-02 Unity Biotechnology, Inc. Klotho polypeptide or polynucleotide for improving cognition
EP4434534A1 (en) 2023-03-22 2024-09-25 ADvantage Therapeutics, Inc. Klotho mrna
WO2025168038A1 (en) * 2024-02-07 2025-08-14 Kunming Institute Of Zoology, Chinese Academy Of Sciences Methods and compositions for ameliorating impairment of regenerative and cognitive function

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110195077A1 (en) * 2010-01-29 2011-08-11 Novartis Ag Methods and compositions using fgf23 fusion ppolypeptides
CN102725413A (zh) * 2010-01-29 2012-10-10 诺瓦提斯公司 使用fgf23融合多肽的方法和组合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452720A (en) 1980-06-04 1984-06-05 Teijin Limited Fluorescent composition having the ability to change wavelengths of light, shaped article of said composition as a light wavelength converting element and device for converting optical energy to electrical energy using said element
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US5330900A (en) 1987-12-31 1994-07-19 Tropix, Inc. Chemiluminescent 3-(substituted adamant-2'-ylidene) 1,2-dioxetanes
US5227487A (en) 1990-04-16 1993-07-13 Molecular Probes, Inc. Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes
ES2281112T3 (es) 1996-12-26 2007-09-16 Kyowa Hakko Kogyo Co., Ltd. Proteina que presenta una actividad de supresion del envejecimiento.
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US20050037954A1 (en) * 2001-03-23 2005-02-17 Masaki Hirashima Novel agents for ameliorating motor disorder
US20040101874A1 (en) 2002-04-12 2004-05-27 Mitokor Inc. Targets for therapeutic intervention identified in the mitochondrial proteome
US20040001859A1 (en) 2002-06-28 2004-01-01 Cheung Ling Yuk Anti-aging dietary supplements
JP2006240990A (ja) 2003-05-15 2006-09-14 Kirin Brewery Co Ltd ｋｌｏｔｈｏタンパク質および抗ｋｌｏｔｈｏタンパク質抗体ならびにそれらの用途
EP2152295B1 (en) 2007-05-08 2018-04-18 Tel HaShomer Medical Research Infrastructure and Services Ltd. Klotho protein and related compounds for the treatment of cancer
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
CN101711779B (zh) * 2008-10-08 2012-12-05 中南大学 垫状卷柏提取物在制备抗阿尔茨海默病药物中的用途
CA2783555A1 (en) 2009-12-16 2011-07-14 Eli Lilly And Company Therapeutic uses of soluble alpha-klotho
JP2012184184A (ja) * 2011-03-04 2012-09-27 Nara Medical Univ 抗老化作用を有するヤドリギ抽出物
AU2015356643B2 (en) 2014-12-04 2019-01-24 Novartis Ag Methods and compositions using Klotho variant polypeptides
CN107405382A (zh) 2015-02-06 2017-11-28 加利福尼亚大学董事会 用于改善认知的方法和组合物
WO2017085317A1 (en) 2015-11-19 2017-05-26 Universitat Autonoma De Barcelona Secreted splicing variant of mammal klotho as a medicament for cognition and behaviour impairments

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110195077A1 (en) * 2010-01-29 2011-08-11 Novartis Ag Methods and compositions using fgf23 fusion ppolypeptides
CN102725413A (zh) * 2010-01-29 2012-10-10 诺瓦提斯公司 使用fgf23融合多肽的方法和组合物

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CI-DI CHEN等: "The Antiaging Protein Klotho Enhances Oligodendrocyte Maturation and Myelination of the CNS", 《THE JOURNAL OF NEUROSCIENCE》 *
ELLA ZELDICH等: "The Neuroprotective Effect of Klotho is Mediated via Regulation of Members of the Redox System", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 *
HIROSHI KUROSU等: "Suppression of Aging in Mice by the Hormone Klotho", 《SCIENCE》 *
NCBI: "klotho precursor [Homo sapiens]", 《NCBI REFERENCE SEQUENCE: NP_004786.2》 *
XI KUANG等: "Klotho upregulation contributes to the neuroprotection of ligustilide in an Alzheimer’s disease mouse model", 《NEUROBIOLOGY OF AGING》 *
周晓辉等: "血清Klotho 蛋白浓度与轻度认知功能障碍的相关研究", 《中华精神科杂志》 *
陈非等: "老年痴呆与Klotho 基因关联性研究进展", 《现代医药卫生》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12239694B2 (en) 2015-02-06 2025-03-04 The Regents Of The University Of California Methods and compositions for improved cognition
CN117797249A (zh) * 2023-11-14 2024-04-02 苏州祥沁医疗科技有限公司 基于mRNA的抗衰老抗老年痴呆预防及治疗疫苗

Also Published As

Publication number Publication date
HK1246193A1 (zh) 2018-09-07
AU2016215080A1 (en) 2017-08-17
AU2016215080B2 (en) 2020-12-24
JP2018509393A (ja) 2018-04-05
WO2016127097A1 (en) 2016-08-11
AU2020281046A1 (en) 2021-01-07
JP6794363B2 (ja) 2020-12-02
EP3253403A4 (en) 2018-09-26
CN121102455A (zh) 2025-12-12
US10864256B2 (en) 2020-12-15
US20210069305A1 (en) 2021-03-11
US20240108698A1 (en) 2024-04-04
EP3253403A1 (en) 2017-12-13
US20250161418A1 (en) 2025-05-22
US10632180B2 (en) 2020-04-28
US20200230214A1 (en) 2020-07-23
CA2974988A1 (en) 2016-08-11
EP3253403B1 (en) 2021-09-01
US11738070B2 (en) 2023-08-29
US12239694B2 (en) 2025-03-04
AU2020281046B2 (en) 2024-04-18
EP3957317A1 (en) 2022-02-23
US10300117B2 (en) 2019-05-28
US20180015151A1 (en) 2018-01-18
US20180256688A1 (en) 2018-09-13

Similar Documents

Publication Publication Date Title
US12239694B2 (en) Methods and compositions for improved cognition
ES2777652T3 (es) Modulación de la actividad de proneurotrofinas
JP2021176883A (ja) 老化関連症状を治療する方法のために使用される医薬組成物
JP5174653B2 (ja) 末梢神経毒症状を処置するためのａｄｎｆポリペプチドの使用
KR20130113962A (ko) 뉴레굴린 이소형, 뉴레굴린 폴리펩타이드 및 이의 용도
CN109134664A (zh) 一种经修饰的生长分化因子及其制备方法和应用
US20230181691A1 (en) Platelet factors and cognitive improvement
ES2569552T3 (es) Composiciones de péptido de MNTF y métodos de uso
KR102919967B1 (ko) 신경 가소성을 유도하기 위한 방법 및 조성물
EP3920887B1 (en) A phosphatidylinositol-glycan-specific phospholipase d1 (gpld1) polypeptide for use in a method of treating or preventing age-related cognitive dysfunction
HK40070785A (en) Methods and compositions for improved cognition
US20230181687A1 (en) Methods and Compositions for Treatment of Age-Related Dysfunction
US20160279204A1 (en) Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disorders
CN121666246A (zh) 质子泵调控剂在制备药物中的用途
WO2026059892A1 (en) Gpx3 as a blood-based calorie restriction mimetic to treat age-related cognitive decline

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1246193

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20171128